Vertex teams up with Skyhawk, leaning on another biotech in bid to diversify

Following a string of deals in edgy, unproven fields of scientific research, Vertex's latest deal involves chemical-based drugs that target RNA — an approach that's already attracted several large pharmas.

By Ben Fidler • Dec. 22, 2020

Changing identity, Agios to sell cancer drug business to Servier

Servier will pay Agios $1.8 billion upfront to acquire the biotech's approved leukemia treatment Tibsovo as well as the rest of its pipeline in cancer and early-stage research work.

By Ned Pagliarulo • Dec. 21, 2020

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

Moderna's first FDA clearance brings the US a second coronavirus vaccine

The FDA's emergency authorization of the biotech's shot bolstered a nascent immunization campaign in the U.S.

By Ben Fidler • Dec. 18, 2020

MacroGenics wins FDA approval of breast cancer drug

Margenza, which bested Roche's Herceptin in a head-to-head study, offers a new option to patients with HER2-positive metastatic breast cancer who have already tried other regimens.

By Kristin Jensen • Dec. 17, 2020

A play-by-play of the FDA meeting on Moderna's coronavirus vaccine

Members of an independent advisory committee voted 20-0 to recommend use of the company's experimental shot, paving the way for an emergency authorization from the FDA.

By Ben Fidler , Jonathan Gardner , Ned Pagliarulo • Updated Dec. 17, 2020

Gilead hands back some rights to key drug from Galapagos deal

The drug, known as filgotinib, recently hit a setback in the U.S., prompting Gilead to lose confidence that it can gain approval or compete against rival medicines in rheumatoid arthritis.

By Jacob Bell • Dec. 16, 2020

Sage replaces CEO Jonas with Alnylam veteran Greene

With Barry Greene, Sage hands the reins to a respected biotech executive who had success in building a commercial organization at Alnylam.

By Kristin Jensen • Dec. 16, 2020

Allogene, broadening its reach, helps start a biotech in China

The cell therapy developer is the second company in two days to form a joint venture with Overland Pharmaceuticals, which aims to bring new drugs to Asia.

By Ben Fidler • Dec. 15, 2020

Relay Therapeutics, fresh off IPO, partners with Roche in cancer drug deal

Roche's interest backs up Relay's bet that understanding how proteins move will help it design better drugs.

By Ned Pagliarulo • Dec. 14, 2020

Lilly's coronavirus drug partner nails down one of biotech's largest IPOs

AbCellera Biologics, a developer of antibody drugs, has raised $483 million through one of the biggest initial public offerings for a biotech in recent years.

By Jacob Bell • Dec. 11, 2020

Gilead inks a billion-dollar deal for a hepatitis drug

Adding to a string of deals, the biotech has agreed to acquire Myr Pharmaceuticals and its marketed drug Hepcludex.

By Jacob Bell • Dec. 10, 2020

Lilly reports strong results for next-generation diabetes drug

Tirzepatide appears very effective at lowering blood sugar, a boost to Lilly's efforts to fend off Novo Nordisk. But the side effects to treatment will need to be closely watched.

By Jonathan Gardner • Dec. 9, 2020

Amgen readies KRAS-blocking cancer drug for FDA filing

The agency agreed to assess sotorasib under a real-time review program that could speed up its evaluation of the closely watched therapy.

By Kristin Jensen • Dec. 9, 2020

Armed with big pharma cash, another startup takes aim at mysterious clusters of molecules

Faze Medicines, which launched Thursday with $81 million in funding, is among a handful of young drug companies focused on the emerging research field of biomolecular condensates.

By Jacob Bell • Dec. 9, 2020

Vaccine Developers of the Year: BioNTech and Moderna

Defying expectations, BioNTech and Moderna each designed and developed highly effective coronavirus shots far faster than previously considered possible.

By Ned Pagliarulo • Dec. 9, 2020

Biotech of the Year: Seagen

A billion-dollar deal with Merck followed quick approvals for the company's second and third drugs, pushing Seagen's market value to over $30 billion.

By Ben Fidler • Dec. 9, 2020

The BioPharma Dive Awards for 2020

Vaccine developers and COVID-19 researchers took center stage in a year turned upside down by the pandemic.

By BioPharma Dive Team • Dec. 9, 2020

In multiple myeloma, cell therapies lead but antibody drugs could follow fast

Two cell therapies might soon be approved for the blood cancer. But a growing group of antibody drugs, several of which were showcased at ASH, aren't far behind.

By Jonathan Gardner , Ben Fidler • Dec. 8, 2020

Sarepta shares first results on next-generation Duchenne drug

The biotech claims early results from a Phase 2 study suggest one of its newer therapies may be more powerful at a lower dose than Exondys 51.

By Kristin Jensen • Dec. 8, 2020

UniQure offers a closer look at the leading hemophilia B gene therapy

Doctors on Tuesday got a more detailed idea of how the therapy works and who might be eligible to take it, as late-stage results were presented at ASH.

By Jacob Bell • Dec. 8, 2020

Lilly to pit Loxo cancer drug against top-selling rival after strong study results

Following positive data at ASH, Lilly will test a drug it acquired in last year's buyout of Loxo Oncology against Imbruvica, one of the world's best-selling cancer treatments.

By Ned Pagliarulo • Dec. 7, 2020

A CRISPR gene editing treatment continues to show promise for two blood diseases

Results from 10 patients with beta thalassemia or sickle cell disease show CRISPR Therapeutics and Vertex's pioneering treatment to be effective, building on earlier study data.

By Ben Fidler • Dec. 5, 2020

4 storylines to track at the year's biggest meeting on blood diseases

A closely watched gene editing therapy, a slate of new multiple myeloma drugs and much more are set to highlight the American Society of Hematology conference this weekend.

By Ben Fidler , Ned Pagliarulo , Jacob Bell • Dec. 3, 2020

Ovid's plan to prove a shelved sleeping pill for a rare disease ends in disappointment

A quest by former Teva and Bristol Myers executive Jeremy Levin to develop an old drug for Angelman's syndrome fell short in a late-stage clinical trial.

By Ben Fidler • Dec. 2, 2020

With anemia data, Agios blood disease drug takes a crucial step forward

Phase 3 results announced Tuesday boost chances that Agios' drug might not just win approval for a rare type of anemia, but also be useful in treating other blood diseases.

By Ben Fidler • Dec. 1, 2020